AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12128042 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 208
Study 10443133 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma homocysteine concentration in Hungary
Number of subjects: 71
Study 10443133 — intervention group
Group type: COMPARATOR
Intervention: Plasma homocysteine concentration in other countries
Number of subjects: 71
Study 10443133 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between plasma homocysteine concentration and cardiovascular mortality
Number of subjects: 71
Study 7797748 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise echocardiography
Number of subjects: 100
Study 7797748 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine echocardiography
Number of subjects: 100
Study 7797748 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole echocardiography
Number of subjects: 100
Study 30003429 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-implemented medication screening tool
Number of subjects: 732
Study 30003429 — intervention group
Group type: COMPARATOR
Intervention: Usual medical and pharmaceutical care
Number of subjects: 732
Study 28817295 — intervention group
Group type: EXPERIMENTAL
Intervention: Plans with zero co-pay tiers for generic statins
Number of subjects: 0
Study 28817295 — intervention group
Group type: COMPARATOR
Intervention: Plans without zero co-pay tiers for generic statins
Number of subjects: 0
Study 28817295 — intervention group
Group type: EXPERIMENTAL
Intervention: Plans with zero co-pay tiers for generic OADs
Number of subjects: 0
Study 26242730 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (40 mg orally every twenty four hours)
Number of subjects: 120
Study 26242730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 26242730 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 120
Study 24217313 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (5,000 U weekly for 8 weeks)
Number of subjects: 70
Study 21334713 — intervention group
Group type: EXPERIMENTAL
Intervention: Overexpression of Forkhead Box M1 transcription factor
Number of subjects: 0
Study 21334713 — intervention group
Group type: EXPERIMENTAL
Intervention: Overexpression of nuclear factor-κB
Number of subjects: 0
Study 21334713 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Forkhead Box M1 transcription factor and nuclear factor-κB
Number of subjects: 0
Study 19615313 — intervention group
Group type: EXPERIMENTAL
Intervention: Feitai Capsule
Number of subjects: 62
Study 19615313 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 62
Study 16534473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysporin
Number of subjects: 33
Study 12720535 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical etidronate therapy in conjunction with anti-rheumatic therapy
Number of subjects: 40
Study 12720535 — intervention group
Group type: COMPARATOR
Intervention: Anti-rheumatic therapy alone (without etidronate)
Number of subjects: 40
Study 11114494 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg buspirone
Number of subjects: 20
Study 11114494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9085299 — intervention group
Group type: EXPERIMENTAL
Intervention: Single burst stimuli (8 mA)
Number of subjects: 9
Study 9085299 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated burst stimuli (5 stimuli at 2 Hz)
Number of subjects: 9
Study 9085299 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous burst stimuli (4 Hz for 30, 60, 90, and 120 s)
Number of subjects: 9
Study 9085299 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated burst stimuli
Number of subjects: 9
Study 9085299 — intervention group
Group type: EXPERIMENTAL
Intervention: Single burst stimuli
Number of subjects: 9
Study 8408474 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin + C-peptide
Number of subjects: 18
Study 8408474 — intervention group
Group type: COMPARATOR
Intervention: Insulin only
Number of subjects: 18
Study 3513531 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg guanfacine daily at bedtime for 8 weeks
Number of subjects: 68
Study 3513531 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 68
Study 29195188 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Cognitive Behavioral Therapy (ICBT)
Number of subjects: 139
Study 29195188 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy (GCBT)
Number of subjects: 139
Study 28664389 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy (HPLT 970 ± 15 nm, 3.2 W (50%), 35-6000 Hz, 240 s for four consecutive days, once a day)
Number of subjects: 16
Study 28664389 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (sham treatment)
Number of subjects: 16
Study 25252696 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 180
Study 25252696 — intervention group
Group type: COMPARATOR
Intervention: Control (uninflated cuffs)
Number of subjects: 180
Study 24601174 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitors (sitagliptin) in combination with metformin
Number of subjects: 18
Study 21227538 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management education intervention (including a self-management workbook, behavioral contract, inhaler training, and telephone reinforcements)
Number of subjects: 296
Study 21227538 — intervention group
Group type: COMPARATOR
Intervention: Control group (instruction from an asthma knowledge test, peak flowmeter training, and asthma brochures)
Number of subjects: 296
Study 21227538 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 296
Study 18296958 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-form strength group (FF n = 10)
Number of subjects: 30
Study 18296958 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed form strength group (FX n = 10)
Number of subjects: 30
Study 18296958 — intervention group
Group type: COMPARATOR
Intervention: Control group (C n = 10)
Number of subjects: 30
Study 17003353 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 IU of vitamin E (alpha‐tocopherol)
Number of subjects: 38716
Study 17003353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38716
Study 12730857 — intervention group
Group type: EXPERIMENTAL
Intervention: Y-27632 (Rho kinase inhibitor)
Number of subjects: 0
Study 11265390 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear function estimation by otoacoustic emission in children treated with cytostatic drugs for leukemia
Number of subjects: 0
Study 11265390 — intervention group
Group type: COMPARATOR
Intervention: Control group of healthy children who have never suffered from ear diseases and have never used ototoxic drugs
Number of subjects: 0
Study 8970026 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 102
Study 8970026 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac
Number of subjects: 102
Study 1335217 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (45 to 60 mg/day)
Number of subjects: 67
Study 1335217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 3882525 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg pirenzepine
Number of subjects: 10
Study 3882525 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg pirenzepine
Number of subjects: 10
Study 3882525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29920688 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Constraint-Induced Movement Therapy (mCIMT)
Number of subjects: 19
Study 29920688 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 19
Study 27436230 — intervention group
Group type: EXPERIMENTAL
Intervention: 250mg d‐cycloserine
Number of subjects: 54
Study 27436230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 25609562 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast eating (5 min)
Number of subjects: 9
Study 25609562 — intervention group
Group type: COMPARATOR
Intervention: Regular eating (15 min)
Number of subjects: 9
Study 24222526 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural treatment (CBT) programme supplemented with culturally sensitive aspects (CsCBT)
Number of subjects: 116
Study 24222526 — intervention group
Group type: COMPARATOR
Intervention: Culturally sensitive exercise therapy (CsET)
Number of subjects: 116
Study 20560907 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics (Bifidobacterium breve M-16V and galacto/fructooligosaccharide mixture)
Number of subjects: 90
Study 20560907 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same formula without synbiotics)
Number of subjects: 90
Study 18498809 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump CABG
Number of subjects: 22
Study 18498809 — intervention group
Group type: COMPARATOR
Intervention: Off-pump CABG
Number of subjects: 22
Study 17293731 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg twice daily
Number of subjects: 0
Study 17293731 — intervention group
Group type: COMPARATOR
Intervention: Bupropion 150 mg twice daily
Number of subjects: 0
Study 17293731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17293731 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 0
Study 15327018 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk individuals for fasting venous plasma glucose (f‐vPG)
Number of subjects: 0
Study 15327018 — intervention group
Group type: COMPARATOR
Intervention: High-risk individuals for fasting venous plasma glucose (f‐vPG)
Number of subjects: 0
Study 11731898 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmechanical trephination (excimer laser, 193-nm, 1.5 x 1.5 mm spot mode, 16-24 mJ/pulse, 25/s)
Number of subjects: 179
Study 11731898 — intervention group
Group type: COMPARATOR
Intervention: Mechanical trephination (motor trephine)
Number of subjects: 179
Study 9142587 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopically inserted intratracheal oxygen (eITO) catheter
Number of subjects: 0
Study 7910322 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosynthetic growth hormone (GH) at 4 IU per m2 per day
Number of subjects: 18
Study 7910322 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosynthetic growth hormone (GH) at 8 IU per m2 per day
Number of subjects: 18
Study 7910322 — intervention group
Group type: COMPARATOR
Intervention: Matched non-GH-treated controls
Number of subjects: 18
Study 7910322 — intervention group
Group type: EXPERIMENTAL
Intervention: GH-treated patients
Number of subjects: 18
Study 7910322 — intervention group
Group type: COMPARATOR
Intervention: Non-GH-treated controls
Number of subjects: 18
Study 3349549 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 ml coffee (Group 1)
Number of subjects: 300
Study 3349549 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 ml orange juice (Group 2)
Number of subjects: 300
Study 3349549 — intervention group
Group type: COMPARATOR
Intervention: Overnight fast (Group 3)
Number of subjects: 300
Study 31577694 — intervention group
Group type: EXPERIMENTAL
Intervention: Coauthorship network analysis
Number of subjects: 2176
Study 31577694 — intervention group
Group type: EXPERIMENTAL
Intervention: Influence metrics
Number of subjects: 2176
Study 31577694 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographical distribution of trialists
Number of subjects: 2176
Study 30496409 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program with spouse's participation
Number of subjects: 128
Study 30496409 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program without spouse's participation
Number of subjects: 128
Study 30496409 — intervention group
Group type: COMPARATOR
Intervention: Routine prenatal care (Control)
Number of subjects: 128
Study 27577562 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentalization-based treatment (MBT)
Number of subjects: 0
Study 27577562 — intervention group
Group type: COMPARATOR
Intervention: Structured clinical management (control)
Number of subjects: 0
Study 24367124 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month collaborative care program involving antidepressants and psychotherapy
Number of subjects: 235
Study 24367124 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 235
Study 22452558 — intervention group
Group type: EXPERIMENTAL
Intervention: High confidence error condition
Number of subjects: 0
Study 22452558 — intervention group
Group type: EXPERIMENTAL
Intervention: Low confidence correct condition
Number of subjects: 0
Study 22452558 — intervention group
Group type: EXPERIMENTAL
Intervention: High confidence wrong answer condition
Number of subjects: 0
Study 22452558 — intervention group
Group type: EXPERIMENTAL
Intervention: Low confidence wrong answer condition
Number of subjects: 0
Study 20473196 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient mailings including a tailored letter, educational brochure, and fecal occult blood test kit at baseline and 6 months follow-up
Number of subjects: 21860
Study 20473196 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 21860
Study 18670227 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined microfinance and training intervention
Number of subjects: 0
Study 16162048 — intervention group
Group type: EXPERIMENTAL
Intervention: High incentive to cheat with high likelihood of getting caught
Number of subjects: 0
Study 16162048 — intervention group
Group type: COMPARATOR
Intervention: Low incentive to cheat
Number of subjects: 0
Study 16162048 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous counterfactual thought
Number of subjects: 0
Study 14748464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg iv 30 min prior to cisplatin, followed by 8 mg orally for 24 h)
Number of subjects: 137
Study 14748464 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (20 mg iv 30 min prior to cisplatin, followed by 20 mg orally for 24 h)
Number of subjects: 137
Study 14748464 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone + Ondansetron
Number of subjects: 137
Study 14748464 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone + Metoclopramide
Number of subjects: 137
Study 14748464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 137
Study 14748464 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 137
Study 10648376 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 81
Study 8873834 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral sulbactam-ampicillin (1.5 g, q.i.d.)
Number of subjects: 74
Study 1954180 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy in patients with more than 10% positive NSE cells
Number of subjects: 114
Study 1954180 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy in patients with Chromogranin A
Number of subjects: 114
Study 1954180 — intervention group
Group type: EXPERIMENTAL
Intervention: NSE-positive cells
Number of subjects: 114
Study 1954180 — intervention group
Group type: EXPERIMENTAL
Intervention: Chr A-positive cells
Number of subjects: 114
Study 6831946 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine
Number of subjects: 15
Study 6831946 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (salbutamol)
Number of subjects: 15
Study 6831946 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of phentolamine and albuterol
Number of subjects: 15
Study 6831946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6831946 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol alone
Number of subjects: 15
Study 31044354 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based environmental interventions modeled from successful home-based interventions
Number of subjects: 0
Study 31044354 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based interventions
Number of subjects: 0
Study 31044354 — intervention group
Group type: EXPERIMENTAL
Intervention: ADA policy and Section 504 of the Rehabilitation Act
Number of subjects: 0
Study 30075513 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 0.6 mg added to 2-day intravenous patient-controlled analgesia (IV-PCA)
Number of subjects: 73
Study 30075513 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 1.2 mg added to 2-day intravenous patient-controlled analgesia (IV-PCA)
Number of subjects: 73
Study 30075513 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic ramosetron (Group C)
Number of subjects: 73
Study 26597598 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C and E supplementation
Number of subjects: 57
Study 26597598 — intervention group
Group type: COMPARATOR
Intervention: Placebo-supplementation
Number of subjects: 57
Study 1360145 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine once a month
Number of subjects: 215
Study 1360145 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole 480 mg once a day
Number of subjects: 215
Study 1360145 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole 960 mg once a day
Number of subjects: 215
Study 1360145 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (both dosages)
Number of subjects: 215
Study 22075088 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard multi-dose hepatitis B vaccine schedule (0, 1, and 6 months)
Number of subjects: 0
Study 22075088 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated hepatitis B vaccine schedule (0, 1, and 2 months)
Number of subjects: 0
Study 22075088 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants aged 40 years or older
Number of subjects: 0
Study 22075088 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants injecting drugs more than once a day
Number of subjects: 0
Study 20345356 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin traction with 2 kg of weights
Number of subjects: 108
Study 20345356 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin traction without weights
Number of subjects: 108
Study 20345356 — intervention group
Group type: EXPERIMENTAL
Intervention: Pillow placement under the affected limb
Number of subjects: 108
Study 17912568 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA + ARA, soy‐based formula supplemented with at least 17 mg DHA/100 kcal and 34 mg ARA/100 kcal
Number of subjects: 244
Study 17912568 — intervention group
Group type: COMPARATOR
Intervention: Control, soy‐based formula without supplementation
Number of subjects: 244
Study 17912568 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA + ARA, soy‐based formula supplemented with DHA and ARA
Number of subjects: 244
Study 15784201 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-restricted condition
Number of subjects: 22
Study 15784201 — intervention group
Group type: COMPARATOR
Intervention: Non-restricted sleep condition
Number of subjects: 22
Study 12456069 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (Cere)
Number of subjects: 109
Study 12456069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 15512377 — intervention group
Group type: EXPERIMENTAL
Intervention: sultrin (sulphathiazole 3.42%, sulphacetamide 2.86%, sulphabenzamide 3.7%) pessaries: one pessary twice daily for 5 days
Number of subjects: 100
Study 15512377 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 100
Study 8743520 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive NIDDM patients
Number of subjects: 146
Study 8743520 — intervention group
Group type: COMPARATOR
Intervention: Normotensive NIDDM patients
Number of subjects: 146
Study 1662266 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg per day for 3 weeks)
Number of subjects: 82
Study 1662266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 2982715 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesotheliomas
Number of subjects: 30
Study 2982715 — intervention group
Group type: COMPARATOR
Intervention: Adenocarcinomas of the lung
Number of subjects: 30
Study 2982715 — intervention group
Group type: COMPARATOR
Intervention: Adenocarcinomas of the breast
Number of subjects: 30
Study 31266486 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic randomized clinical trials (PCTs)
Number of subjects: 0
Study 31266486 — intervention group
Group type: EXPERIMENTAL
Intervention: Modifications in study designs for PCTs
Number of subjects: 0
Study 31266486 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified informed consent procedures
Number of subjects: 0
Study 31266486 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified regulatory and oversight procedures
Number of subjects: 0
Study 29760286 — intervention group
Group type: EXPERIMENTAL
Intervention: FemoSeal Vascular Closure Device (VCD)
Number of subjects: 3018
Study 29760286 — intervention group
Group type: COMPARATOR
Intervention: Manual Compression
Number of subjects: 3018
Study 29760286 — intervention group
Group type: EXPERIMENTAL
Intervention: FemoSeal VCD
Number of subjects: 3018
Study 27052530 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy diet (3 servings/d of dairy: 375 mL 1% milk-fat milk, 175 g 1.5% MF yogurt, and 30 g of 34% MF cheese)
Number of subjects: 101
Study 27052530 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy diet
Number of subjects: 101
Study 27052530 — intervention group
Group type: COMPARATOR
Intervention: Energy-matched control products (juice, cashews, and cookies)
Number of subjects: 101
Study 25204404 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate 1,000 mg/day
Number of subjects: 359
Study 25204404 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 359
Study 22739534 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine buffered with citric acid (ARG.CITR)
Number of subjects: 23
Study 22739534 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine buffered with HCl (ARG.HCl)
Number of subjects: 23
Study 21057255 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based pediatric obesity program (treatment group)
Number of subjects: 155
Study 20966444 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (total IV anesthesia)
Number of subjects: 134